INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47601, 30409, 'Diltiazem', 'Heart Failure', 'Diltiazem has demonstrated a negative inotropic effect in isolated animal tissue preparations but rarely in clinical situations.  Hemodynamic studies in humans with normal ventricular function and in patients with a compromised myocardium have not shown a reduction in cardiac index nor consistent negative effects on contractility.  However, worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function.  Therapy with diltiazem should be administered cautiously, if at all, in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, diltiazem should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating diltiazem therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47602, 30410, 'Diltiazem', 'Heart Failure', 'Diltiazem has demonstrated a negative inotropic effect in isolated animal tissue preparations but rarely in clinical situations.  Hemodynamic studies in humans with normal ventricular function and in patients with a compromised myocardium have not shown a reduction in cardiac index nor consistent negative effects on contractility.  However, worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function.  Therapy with diltiazem should be administered cautiously, if at all, in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, diltiazem should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating diltiazem therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47603, 449, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47604, 3697, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47605, 6926, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47606, 11249, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47607, 14183, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47608, 17194, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47609, 17195, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47610, 17196, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47611, 17230, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47612, 17231, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47613, 17232, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47614, 27095, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47615, 27096, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47616, 27097, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47617, 27997, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47618, 30409, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47619, 30410, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47620, 449, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47621, 3697, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47622, 6926, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47623, 11249, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47624, 14183, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47625, 17194, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47626, 17195, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47627, 17196, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47628, 17230, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47629, 17231, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47630, 17232, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47631, 27095, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47632, 27096, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47633, 27097, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47634, 27997, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47635, 30409, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47636, 30410, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47637, 449, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47638, 3697, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47639, 6926, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47640, 11249, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47641, 14183, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47642, 17194, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47643, 17195, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47644, 17196, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47645, 17230, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47646, 17231, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47647, 17232, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47648, 27095, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47649, 27096, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47650, 27097, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47651, 27997, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47652, 30409, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47653, 30410, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47654, 0, 'Dinutuximab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47655, 0, 'Dinutuximab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47656, 0, 'Dinutuximab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47657, 0, 'Dinutuximab', 'Water-Electrolyte Imbalance', 'Dinutuximab can cause electrolytes abnormalities, including hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia.  Electrolyte abnormalities should be corrected prior to initiating nilotinib and should be monitored daily during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47658, 0, 'Dinutuximab', 'Hemolytic-Uremic Syndrome', 'Atypical hemolytic uremic syndrome in the absence of documented infection and resulting in renal insufficiency, electrolyte abnormalities, anemia, and hypertension can occur in patients treated with dinutuximab.  Atypical hemolytic uremic syndrome has recurred following rechallenge with dinutuximab.  Permanently discontinue therapy and institute supportive management for signs of hemolytic uremic syndrome.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47659, 0, 'Dinutuximab', 'Hypotension', 'Hypotension has been observed during therapy with dinutuximab.  This drug should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.  It is recommended to administer required intravenous hydration prior to each infusion and to closely monitor blood pressure during treatment.  Interruption or discontinuation of treatment might be necessary if systolic blood pressure is less than lower limit of normal for age, or if it decreases by more than 15% compared to baseline.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47660, 0, 'Dinutuximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of dinutuximab.  In a clinical study, severe thrombocytopenia, anemia, neutropenia occurred more frequently in patients treated with dinutuximab/13-cis-retinoic acid group compared to those treated with 13-cis-retinoic acid alone.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47661, 0, 'Dinutuximab', 'Neurotoxicity Syndromes', 'Dinutuximab causes serious neurologic adverse reactions including, severe neuropathic pain, peripheral neuropathy, neurologic disorders of the eye, prolong urinary retention, and transverse myelitis.  Discontinue treatment for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy.  It might be necessary to permanently discontinue treatment in certain cases.  Care should be exercised when prescribing this agent to patients at risk for neurotoxicity.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47662, 0, 'Dinutuximab', 'Posterior Leukoencephalopathy Syndrome', 'The use of dinutuximab may cause reversible posterior leukoencephalopathy syndrome (RPLS).  Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS.  It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47663, 17682, 'Dinoprostone (topical)', 'Asthma', 'The use of dinoprostone may be associated with bronchospasm, decreased pulmonary blood flow, and/or increased pulmonary arterial pressure.  Dinoprostone induces contraction of smooth muscle, including smooth muscle of the respiratory tract.  Therapy with dinoprostone should be administered cautiously in patients with asthma, or history of childhood asthma, even in the absence of asthma attacks in adulthood.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47664, 25362, 'Dinoprostone (topical)', 'Asthma', 'The use of dinoprostone may be associated with bronchospasm, decreased pulmonary blood flow, and/or increased pulmonary arterial pressure.  Dinoprostone induces contraction of smooth muscle, including smooth muscle of the respiratory tract.  Therapy with dinoprostone should be administered cautiously in patients with asthma, or history of childhood asthma, even in the absence of asthma attacks in adulthood.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47665, 28893, 'Dinoprostone (topical)', 'Asthma', 'The use of dinoprostone may be associated with bronchospasm, decreased pulmonary blood flow, and/or increased pulmonary arterial pressure.  Dinoprostone induces contraction of smooth muscle, including smooth muscle of the respiratory tract.  Therapy with dinoprostone should be administered cautiously in patients with asthma, or history of childhood asthma, even in the absence of asthma attacks in adulthood.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47666, 17682, 'Dinoprostone (topical)', 'Hypotension', 'Therapy with dinoprostone should be administered cautiously in patients with a history of hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47667, 25362, 'Dinoprostone (topical)', 'Hypotension', 'Therapy with dinoprostone should be administered cautiously in patients with a history of hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47668, 28893, 'Dinoprostone (topical)', 'Hypotension', 'Therapy with dinoprostone should be administered cautiously in patients with a history of hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47669, 17682, 'Dinoprostone (topical)', 'Glaucoma', 'Caution should be exercised when administering dinoprostone topical in patients with a history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47670, 25362, 'Dinoprostone (topical)', 'Glaucoma', 'Caution should be exercised when administering dinoprostone topical in patients with a history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47671, 28893, 'Dinoprostone (topical)', 'Glaucoma', 'Caution should be exercised when administering dinoprostone topical in patients with a history of glaucoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47672, 0, 'Altretamine', 'Bone Marrow Failure Disorders', 'The use of altretamine is contraindicated in patients with severe bone marrow suppression.  Altretamine induces mild to moderate dose-related myelosuppression.  If white blood cell counts fall below 2000/mm3 and/or platelet counts fall below 75,000/mm3 during altretamine therapy, subsequent doses should be withheld at least 14 days and altretamine restarted at 200 mg/m2/day.  Clinical monitoring of hematopoietic function is recommended prior to each course of altretamine and the dose should be adjusted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47673, 0, 'Altretamine', 'Neurologic Manifestations', 'The use of altretamine is contraindicated in patients with severe neurological impairment.  Peripheral neuropathy as well as central nervous system symptoms of ataxia, vertigo, mood disorders, and disorders of consciousness has been noted during administration of altretamine.  However, altretamine has been administered safely to patients with cisplatin-associated neuropathy and to patients administered other alkylating agents.  Clinical monitoring of neurologic function should be performed prior to the initiation of each course of therapy and the dose adjusted as clinically indicated in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47674, 0, 'Altretamine', 'Hepatic Insufficiency', 'Altretamine is well-absorbed following oral administration in humans, but undergoes rapid and extensive demethylation in the liver, producing variation in altretamine plasma levels.  Patients with liver disease may be at higher risk for adverse effects from altretamine.  Caution is recommended when using this drug in patients with hepatic impairment as the pharmacokinetics of altretamine has not been evaluated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47675, 0, 'Dipivefrin (ophthalmic)', 'Aphakia', 'Up to 30% of aphakic patients treated chronically with ophthalmic epinephrine (of which dipivefrin is a prodrug) may develop cystoid macular edema, which is generally reversible following withdrawal of the medication.  Ophthalmic epinephrine preparations should be administered cautiously with appropriate monitoring in patients with aphakia.  Therapy should be discontinued if blurred or distorted vision, central scotoma, and/or loss of visual acuity occur.  Slight visual impairment may respond to a reduction in the concentration or frequency of administration of the drug.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47676, 0, 'Dipivefrin (ophthalmic)', 'Glaucoma, Angle-Closure', 'The use of ophthalmic preparations of epinephrine, including dipivefrin (a prodrug of epinephrine), is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  These agents stimulate both alpha-1 and alpha-2 adrenergic receptors, thus topical administration can induce transient mydriasis, either with or without the use of concomitant miotic agents.  In patients with narrow angles, any degree of pupillary dilation can provoke an acute attack of angle-closure glaucoma.  In contrast, sympathomimetic agents with relative alpha-2 adrenergic selectivity such as apraclonidine and brimonidine produce little to no mydriasis at normally recommended dosages.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47677, 0, 'Disulfiram', 'Alcoholic Intoxication', 'The administration of disulfiram is contraindicated in patients in a state of alcohol intoxication.  The disulfiram- alcohol reaction may produce symptoms including flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion.  Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47678, 0, 'Disulfiram', 'Heart Diseases', 'The use of disulfiram is contraindicated in patients with cardiac disease.  The potential for a disulfiram- alcohol reaction, symptoms of which can include cardiovascular effects such as palpitation, tachycardia, chest pain, hypotension, syncope and, in severe cases, cardiovascular collapse, arrhythmias, myocardial infarction, and acute congestive heart failure, may present a particular danger to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47679, 0, 'Disulfiram', 'Psychotic Disorders', 'The use of disulfiram is contraindicated in patients with psychosis.  Disulfiram may precipitate psychotic reactions and mood disorders, particularly when given in high dosages or with metronidazole or isoniazid.  In some cases, however, the sudden withdrawal of alcohol alone can unmask underlying psychotic disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47680, 0, 'Disulfiram', 'Liver Diseases', 'Hepatic toxicity, hepatitis, and hepatic failure resulting in transplantation or death have been reported with the use of disulfiram.  Hepatic toxicity has occurred in patient with and without prior history of abnormal liver function.  Extreme caution and close monitoring is advised if used in patients with liver impairment.  Baseline and liver tests are suggested in all patients to detect any hepatic abnormalities.  Patients should be advised to immediately notify their health provider if any symptoms of hepatitis occur (weakness, fatigue, anorexia, nausea, vomiting, jaundice, or dark urine).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47681, 14102, 'Dipyridamole', 'Bronchial Spasm', 'Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD).  Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47682, 24773, 'Dipyridamole', 'Bronchial Spasm', 'Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD).  Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47683, 25193, 'Dipyridamole', 'Bronchial Spasm', 'Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD).  Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47684, 14102, 'Dipyridamole', 'Long QT Syndrome', 'Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm.  There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block.  Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events.  Caution is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47685, 24773, 'Dipyridamole', 'Long QT Syndrome', 'Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm.  There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block.  Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events.  Caution is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47686, 25193, 'Dipyridamole', 'Long QT Syndrome', 'Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm.  There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block.  Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events.  Caution is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47687, 14102, 'Dipyridamole', 'Hypotension', 'Dipyridamole can cause peripheral vasodilation.  Therapy with dipyridamole should be administered cautiously in patients with hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47688, 24773, 'Dipyridamole', 'Hypotension', 'Dipyridamole can cause peripheral vasodilation.  Therapy with dipyridamole should be administered cautiously in patients with hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47689, 25193, 'Dipyridamole', 'Hypotension', 'Dipyridamole can cause peripheral vasodilation.  Therapy with dipyridamole should be administered cautiously in patients with hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47690, 14102, 'Dipyridamole', 'Myasthenia Gravis', 'Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole.  Caution should be exercised with these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47691, 24773, 'Dipyridamole', 'Myasthenia Gravis', 'Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole.  Caution should be exercised with these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47692, 25193, 'Dipyridamole', 'Myasthenia Gravis', 'Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole.  Caution should be exercised with these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47693, 4029, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47694, 12592, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47695, 18113, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47696, 27123, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47697, 29689, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47698, 4029, 'Docusate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47699, 12592, 'Docusate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47700, 18113, 'Docusate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
